###begin article-title 0
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
The spectrum of phenotypes associated with mutations in steroidogenic factor 1 (SF-1, NR5A1, Ad4BP) includes severe penoscrotal hypospadias in 46,XY males without adrenal insufficiency
###end article-title 0
###begin title 1
Objective
###end title 1
###begin p 2
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 354 358 <span type="species:ncbi:9606">boys</span>
Hypospadias is a frequent congenital anomaly but in most cases an underlying cause is not found. Steroidogenic factor 1 (SF-1, NR5A1, Ad4BP) is a key regulator of human sex development and an increasing number of SF-1 (NR5A1) mutations are reported in 46,XY disorders of sex development (DSD). We hypothesized that NR5A1 mutations could be identified in boys with hypospadias.
###end p 2
###begin title 3
Design and methods
###end title 3
###begin p 4
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
Mutational analysis of NR5A1 in 60 individuals with varying degrees of hypospadias from the German DSD network.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 850 856 850 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 609 616 <span type="species:ncbi:9606">patient</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
Heterozygous NR5A1 mutations were found in three out of 60 cases. These three individuals represented the most severe end of the spectrum studied as they presented with penoscrotal hypospadias, variable androgenization of the phallus and undescended testes (three out of 20 cases (15%) with this phenotype). Testosterone was low in all three patients and inhibin B/anti-Mullerian hormone (AMH) were low in two patients. Two patients had a clear male gender assignment. Gender re-assignment to male occurred in the third case. Two patients harbored heterozygous nonsense mutations (p.Q107X/WT, p.E11X/WT). One patient had a heterozygous splice site mutation in intron 2 (c.103-3A/WT) predicted to disrupt the main DNA-binding motif. Functional studies of the nonsense mutants showed impaired transcriptional activation of an SF-1-responsive promoter (Cyp11a). To date, adrenal insufficiency has not occurred in any of the patients.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
SF-1 (NR5A1) mutations should be considered in 46,XY individuals with severe (penoscrotal) hypospadias, especially if undescended testes, low testosterone, or low inhibin B/AMH levels are present. SF-1 mutations in milder forms of idiopathic hypospadias are unlikely to be common.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 145 151 145 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1 bib2">(1, 2)</xref>
###xml 64 68 <span type="species:ncbi:9606">boys</span>
Hypospadias is one of the most frequent congenital anomalies in boys, occurring with a frequency of approximately one in every 250 newborn males (1, 2). The clinical spectrum of this condition ranges from severe forms, where the urethra opens in the scrotum or penoscrotal junction, to milder forms, where the urethral opening is located on the penile midshaft or glans. Some cases of hypospadias are associated with specific syndromic features and, in some cases, underdevelopment of the phallus and/or undescended testes may be present.
###end p 10
###begin p 11
###xml 150 153 150 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">(3)</xref>
###xml 299 318 299 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SHH, HOXA13, HOXD13</italic>
###xml 499 502 499 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">(4)</xref>
###xml 673 679 673 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5 bib6">(5, 6)</xref>
###xml 1017 1023 1017 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7 bib8 bib9 bib10 bib11 bib12">(7&#8211;12)</xref>
###xml 1262 1265 1262 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 1395 1403 1395 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13 bib14">(13, 14)</xref>
###xml 143 149 <span type="species:ncbi:9606">humans</span>
###xml 639 645 <span type="species:ncbi:9606">humans</span>
###xml 1031 1039 <span type="species:ncbi:9606">patients</span>
###xml 1350 1358 <span type="species:ncbi:9606">patients</span>
Hypospadias results from a ventral fusion defect of the urethra during embryonic development, which occurs between 8 and 12 weeks gestation in humans (3). The first phase of elongation and patterning of the genital tubercle occurs in both sexes and is mainly controlled by developmental genes (e.g. SHH, HOXA13, HOXD13) and local growth factors (e.g. FGF8, FGF10, FGFR-IIIB, BMP7). The second phase of phallic growth occurs in males under the influence of androgen (dihydrotestosterone, DHT) action (4). In rare cases, a defect in one of these factors has been found to be associated with syndromic or nonsyndromic forms of hypospadias in humans (e.g. HOXA13, FGF8, FGFR2) (5, 6). Similarly, variable loss-of-function changes in the transcription factors, receptors, and enzyme pathways involved in Leydig cell development, androgen biosynthesis, and androgen action have also been found to be a cause of hypospadias in a few individuals (e.g. CXorf6, LHCGR, STAR, CYP11A1, HSD3B2, CYP17A1, POR, HSD17B3, SRD5A2, AR) (7-12). These patients often have associated micropenis and unilateral or bilateral cryptorchidism as androgens are implicated in phallic growth and the second stage of testis descent. Furthermore, mutations in the Wilms' tumor suppressor gene (WT1), a gene that plays a role in testis and kidney development, have been described in patients with hypospadias and kidney disease (13, 14).
###end p 11
###begin p 12
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">(15)</xref>
###xml 590 595 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 669 673 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">(16)</xref>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 984 991 984 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17 bib18 bib19">(17&#8211;19)</xref>
###xml 1031 1036 1031 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
Despite advances in our understanding of these developmental processes, the exact etiology of hypospadias remains unknown in most cases. It is quite possible that multifactorial influences are important, and environmental modulators of the androgen/estrogen pathway (e.g. pesticides) have been implicated in the potential population increase in this condition (15). However, it is plausible that other single gene disorders may result in hypospadias, either alone or as part of an oligogenic network. One key candidate gene known to be involved in testis development and steroidogenesis is NR5A1, which encodes the nuclear receptor steroidogenic factor 1 (SF-1, Ad4BP) (16). Mutations in NR5A1 are emerging as a relatively frequent cause of some forms of 46,XY disorders of sex development (DSD; partial testicular dysgenesis, impaired androgen synthesis) and in most cases reported to date, the underandrogenization has been sufficiently severe to lead to a female gender assignment (17-19). Here, we investigate the frequency of NR5A1 mutations in a cohort of individuals with severe penile or penoscrotal hypospadias.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 14
###begin p 15
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
The cohort studied consisted of 60 46,XY DSD patients from the 'German Network of Disorders of Sex Development' who had presented at birth with variable degrees of hypospadias ranging from severe penile to penoscrotal forms. Twenty-four patients had penile hypospadias. Of these, 18 patients had descended testes and six patients had at least one undescended testis. Thirty-six patients had peno-scrotal hypospadias. Of these, 16 patients had descended testes and 20 patients had at least one undescended testis. Adrenal insufficiency, other endocrine disorders or syndromic features were not reported in any of these patients. Ethical review board approval was granted and informed consent was obtained from all parents according to institutional guidelines.
###end p 15
###begin title 16
Molecular analysis of NR5A1
###end title 16
###begin p 17
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">(18)</xref>
Genomic DNA was extracted from peripheral blood leukocytes using a Qiamp DNA blood kit (Qiagen). Direct sequencing of the six coding exons of NR5A1 (exons 2-7) was performed as described previously (18).
###end p 17
###begin title 18
Splice-site mutation
###end title 18
###begin p 19
Genscan splice prediction software () was used to assess the consequences of the splice site mutation detected.
###end p 19
###begin title 20
Transient gene expression assays
###end title 20
###begin p 21
###xml 666 672 666 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 910 917 910 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 965 971 963 969 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s.e.m.</sc>
###xml 493 498 <span type="species:ncbi:9606">human</span>
Expression vectors containing the p.E11X or p.Q107X nonsense mutants were generated by site-directed mutagenesis (QuikChange, Stratagene, Amsterdam, The Netherlands) using wild-type (WT) pCMXSF-1 as a template. The entire coding sequence was confirmed by direct sequencing prior to functional analyses. Transient transfection studies were performed in 96-well plates using lipofectamine 2000 (Invitrogen) and a dual-luciferase reporter assay system (Promega). Studies were performed in tsa201 human embryonic kidney cells by transfecting empty, WT, or mutant SF-1 expression vectors (2 ng/well; p.G35E, p.E11X, p.Q107X,) with the SF-1-responsive minimal promoter of Cyp11a linked to luciferase (100 ng/well). Cells were lysed 24 h following transfection and assayed for luciferase activity (Dual Luciferase Reporter Assay system, Promega; FLUOstar Optima, BMG Labtech, Aylesbury, UK), with standardization for Renilla co-expression. Results are shown as the mean+/-s.e.m. of three independent experiments, each performed in triplicate.
###end p 21
###begin title 22
Studies of SF-1 nuclear localization
###end title 22
###begin p 23
Mutant GFP-SF-1 constructs were generated by site-directed mutagenesis in a pAcGFP-C1 vector (Clontech) to produce mutant fusion proteins with a GFP tag at the amino-terminus of SF-1. WT and mutant pAcGFP-C1SF-1 expression vectors (0.8 mug) were transfected into tsa201 cells. After 24 h, cells were fixed and nuclear counterstaining performed with Vectashield containing DAPI (Vector Laboratories, Peterborough, UK) (data not shown).
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
Cohort analysis
###end title 25
###begin p 26
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 140 147 140 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
SF-1 (NR5A1) mutations were found in 3 out of 60 (5%) patients studied. An overview of these changes and clinical phenotypes is provided in Table 1. Of note, these changes were found only in patients with severe penoscrotal hypospadias and undescended testes (3 out of 20, 15%). No SF-1 mutations were found in this cohort in those patients with penile hypospadias and/or bilaterally descended testes.
###end p 26
###begin title 27
Case histories
###end title 27
###begin p 28
###xml 273 280 273 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 944 951 944 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 1873 1880 1873 1880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 288 295 <span type="species:ncbi:9606">patient</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 656 664 <span type="species:ncbi:9606">patients</span>
###xml 703 708 <span type="species:ncbi:9606">human</span>
###xml 764 772 <span type="species:ncbi:9606">patients</span>
###xml 796 803 <span type="species:ncbi:9606">patient</span>
###xml 872 879 <span type="species:ncbi:9606">patient</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
###xml 1081 1088 <span type="species:ncbi:9606">patient</span>
###xml 1255 1263 <span type="species:ncbi:9606">patients</span>
###xml 1265 1272 <span type="species:ncbi:9606">patient</span>
###xml 1298 1305 <span type="species:ncbi:9606">patient</span>
###xml 1329 1336 <span type="species:ncbi:9606">patient</span>
###xml 1551 1558 <span type="species:ncbi:9606">Patient</span>
###xml 1904 1911 <span type="species:ncbi:9606">patient</span>
###xml 1933 1937 <span type="species:ncbi:9606">girl</span>
###xml 2361 2368 <span type="species:ncbi:9606">patient</span>
###xml 2468 2476 <span type="species:ncbi:9606">patients</span>
All three patients were diagnosed with severe hypospadias and undescended inguinal testes at birth. Subject 1 had a normal penile length at birth whereas subjects 2 and 3 both had a small phallus (subject 2, 2.5 cm, -2.5 SDS at birth; subject 3, 2 cm, -3.8 SDS at 4 years; Table 1). Only patient 2 displayed a minimal chordee. In all the cases, there was a single opening at the base of phallus with no vaginal introitus. Complete scrotal midline fusion was seen in all patients, although the scrotum was slightly hypoplastic with decreased plication in patients 2 and 3. Endocrine evaluation at diagnosis showed low basal testosterone levels in all three patients and impaired testosterone response to human chorionic gonadotrophin (hCG) stimulation when tested (patients 2 and 3). Furthermore, patient 1 had low anti-Mullerian hormone (AMH) levels at 4 years of age and patient 2 had low inhibin B and slightly elevated FSH at 7 days of age (Table 1). No Mullerian structures were found by ultrasound in patients 1 and 3, whereas a uterine remnant was suspected by ultrasound in patient 2, which was revealed to be a vaginal rest by genitography and laparoscopy. Bilateral inguinal gonads consistent with the testes were seen by ultrasound in all three patients (patient 1, 2 ml/2 ml at 4 years; patient 2, 1 ml/1 ml at birth; patient 3, 3 ml/3 ml at 4 years). As testicular architecture appeared normal, no biopsies were performed. Male gender assignment was made in subjects 1 and 2 at birth and hypospadias repair and orchidopexy was undertaken. Patient 3 was born in a rural area of Egypt and presented to the National Research Center of Cairo at the age of 4 years. At that time, a small phallus (2 cm), penoscrotal hypospadias and inguinal testes were seen. The karyotype was 46,XY, testosterone was low before and after hCG stimulation, and no uterus was present (Table 1). Until this point the patient had been raised as a girl but gender reassignment was considered based on the clinical features, investigations, and parental views. A trial of DHT cream (Andractim 2.5%, applied to the phallus once daily at a dose of approximately5-10 mg daily) resulted in an increase in phallic length from 2 to 2.5 cm and gender reassigment to male is currently in progress. Of note, basal cortisol, 17-hydroxyprogesterone and DHEAS were within normal ranges in patient 1 and 2 at diagnosis, and no symptoms or signs of adrenal insufficiency have emerged in any of the patients during follow up.
###end p 28
###begin title 29
SF-1 (NR5A1) mutations detected
###end title 29
###begin p 30
###xml 154 160 154 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 279 280 279 280 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</underline>
###xml 295 296 295 296 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</underline>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 164 171 <span type="species:ncbi:9606">Patient</span>
###xml 307 314 <span type="species:ncbi:9606">Patient</span>
Patient 1 has a heterozygous C to T substitution in exon 4 (c.319 C>T) resulting in a change from glutamine to a stop codon at position 107 (p.Q107X/WT) (Fig. 1A). Patient 2 has a heterozygous C to A substitution within the splice acceptor site of intron 2 (c.103-3C>A/WT; ctcccgcagGGCTTC>ctcccgaagGGCTTC). Patient 3 has a heterozygous G to T substitution in exon 2 (c.31G>T) resulting in a change from glutamate to a stop codon at position 11 (p.E11X/WT). Analysis of DNA from 100 healthy control subjects (200 alleles) did not detect any of these novel changes by restriction analysis.
###end p 30
###begin title 31
Functional studies of SF-1 activity (p.E11X, p.Q107X)
###end title 31
###begin p 32
###xml 143 149 143 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 332 338 332 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 380 386 380 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
The two nonsense mutants studied (p.E11X, p.Q107X) showed markedly impaired transcriptional activity in an established assay of SF-1 function (Fig. 1B). Although these changes might be subject to nonsense mediated-decay, any translated p.E11X or p.Q107X protein would be predicted to lack of most of the functional domains of SF-1 (Fig. 1A) and have altered nuclear localization (Fig. 1C).
###end p 32
###begin title 33
Altered splicing (c.103-3C>A)
###end title 33
###begin p 34
###xml 344 347 344 347 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPK</underline>
Using Genscan splice prediction software, the c.103-3C>A change is likely to affect splicing at the intron 2-exon 3 splice acceptor site. Potentially, an additional three amino acids (LPK) are inserted into the first zinc finger of the SF-1 protein. This insertion between codons 34 and 35 would disrupt the proximal ('P') box motif (ESCKG>ESCKLPKG), the critical DNA binding region of SF-1.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 336 344 336 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19 bib20">(19, 20)</xref>
###xml 411 416 411 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 680 695 680 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17 bib18 bib21 bib22 bib23 bib24 bib25 bib26">(17, 18, 21&#8211;26)</xref>
###xml 792 796 792 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">(27)</xref>
###xml 267 273 <span type="species:ncbi:9606">humans</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 638 643 <span type="species:ncbi:9606">girls</span>
###xml 647 652 <span type="species:ncbi:9606">women</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 785 791 <span type="species:ncbi:9606">humans</span>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
Steroidogenic factor 1 (NR5A1) is a transcription factor that plays a central role in gonadal and adrenal development. SF-1 also regulates the transcription of several enzymes involved in steroid/androgen biosynthesis. Although the initial search for SF-1 changes in humans focused on patients with combined gonadal and adrenal failure (19, 20), more recent case reports and series have shown that heterozygous NR5A1 (SF-1) mutations can be found relatively frequently in 46,XY patients with severe underandrogenization, mild or partial gonadal dysgenesis, impaired androgen synthesis, and apparently normal adrenal function, or in 46,XX girls or women with ovarian insufficiency (17, 18, 21-26). Thus, patients with SF1 mutations can present with a predominantly gonadal phenotype in humans (27). So far, most of the reported patients with severe underandrogenization have been raised as females.
###end p 36
###begin p 37
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">(17)</xref>
###xml 593 600 593 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28 bib29 bib30">(28&#8211;30)</xref>
###xml 130 137 <span type="species:ncbi:9606">patient</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
A spectrum of phenotypes exists for most developmental endocrine conditions. As we have reported a SF-1 mutation (p.L437Q) in one patient (penoscrotal hypospadias, high scrotal testes) who was raised male, we hypothesized that loss-of-function mutations in SF-1 might also be found in 46,XY patients with hypospadias but without adrenal failure (17). Indeed, a milder loss of function change in SF-1 has been reported in association with micropenis and bilateral anorchia, and a nonsynonymous polymorphism in SF-1 may be associated with micropenis and undescended testes in population studies (28-30).
###end p 37
###begin p 38
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 963 968 963 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 1527 1539 1527 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19 bib20 bib31">(19, 20, 31)</xref>
###xml 2055 2060 2055 2060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 17 25 <span type="species:ncbi:9606">children</span>
###xml 354 361 <span type="species:ncbi:9606">patient</span>
###xml 543 550 <span type="species:ncbi:9606">patient</span>
###xml 685 692 <span type="species:ncbi:9606">Patient</span>
###xml 763 770 <span type="species:ncbi:9606">patient</span>
###xml 986 994 <span type="species:ncbi:9606">children</span>
###xml 1060 1068 <span type="species:ncbi:9606">children</span>
###xml 1217 1225 <span type="species:ncbi:9606">patients</span>
###xml 1295 1303 <span type="species:ncbi:9606">patients</span>
###xml 1391 1399 <span type="species:ncbi:9606">patients</span>
###xml 1590 1598 <span type="species:ncbi:9606">patients</span>
In the cohort of children with a range of nonsyndromic hypospadiac disorders described here, novel heterozygous SF-1 (NR5A1) mutations were found in 5% (3/60) of the entire group, and in 3/20 (15%) of those with the most severe phenotype comprising severe penoscrotal hypospadias, small to normal phallus, inguinal testes and low testosterone levels. In patient 2 gonadal dysgenesis was present at birth as reflected by the low inhibin B, AMH and testosterone levels and the presence of a vaginal rest as a rudimentary Mullerian structure. In patient 1, the decreased testosterone level at birth and the low amount of inhibin B in infancy may represent progressive gonadal dysgenesis. Patient 1 and 2 were raised as males from birth, whereas gender assignment in patient 3 was more challenging on account of a delayed presentation and the greater degree of genital ambiguity. Taken together, these cases show that heterozygous loss-of-function mutations in SF-1 (NR5A1) can be found in children with severe forms of hypospadias and that male sex of rearing of children with SF-1 mutations is possible, but SF-1 mutations are not found frequently in association with minor forms of hypospadias. To date, none of these patients have shown evidence of adrenal insufficiency, and it is uncertain if patients with SF-1 mutations are at risk of developing adrenal insufficiency in later life. Two patients with 46,XY DSD and adrenal failure have been reported, which may reflect more significant loss of SF-1 function in these cases (19, 20, 31). Furthermore, it is unknown if DSD or hypospadiac patients with SF-1 mutations will have normal puberty and fertility or if there is an increased risk of testicular tumors due to gonadal dysgenesis. Subsequently, individuals with SF-1 mutations need long-term follow-up of adrenal and hypothalamic-pituitary-gonadal function and regular screening for gonadal tumors. In some individuals, sex assignment is challenging and long-term studies of gender identity and psychosexual functioning are needed. Thus, defining NR5A1 (SF-1) mutations of this group of individuals with severe hypospadias may have important implications in their later life, although further research is needed before specific guidelines or recommendations for genetic screening can be made.
###end p 38
###begin p 39
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">(32)</xref>
###xml 652 658 652 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 661 669 661 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18 bib33">(18, 33)</xref>
###xml 1135 1139 1135 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">(34)</xref>
###xml 1412 1416 1412 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">(19)</xref>
###xml 1303 1310 <span type="species:ncbi:9606">patient</span>
In addition to the clinical implications of these findings, the identification of these three novel NR5A1 changes provides some insight into the biological function of SF-1. RNA containing the c.31G>T (p.E11X) or c.319 C>T (p.Q107X) changes may be subject to nonsense mediated decay as well as loss of key functional domains in any translated protein (32). However, these naturally occurring changes, taken together with the previously reported p.Y138X mutation, support the hypothesis that the nuclear localization signal of SF-1 requires integrity of a bipartite basic motif around codons 89-101 in the distal DNA-binding and proximal hinge regions (Fig. 1C) (18, 33). Thus, the p.E11X mutant protein is located throughout the cell, whereas the p.Q107X protein is largely nuclear and the p.Y138X protein exclusively so. In contrast, the c.103-3C>A splice acceptor site change is predicted to generate a novel translated protein with insertion of three amino acids into the P-box (proximal) of the DNA-binding domain. This P-box motif is crucial for major groove binding and for dictating target gene specificity by nuclear receptors (34). However, the effects of splice site changes are often not complete and some normal protein is produced, which may contribute to the milder phenotype seen in this patient compared with the previously described individual with a p.G35E missense mutation in the P-box motif (19). It is also likely that modifier genes or epigenetic or environmental factors can influence individual phenotypes on top of a background of SF-1 haploinsufficiency.
###end p 39
###begin title 40
Declaration of interest
###end title 40
###begin p 41
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
###end p 41
###begin title 42
Funding
###end title 42
###begin p 43
###xml 160 168 <span type="species:ncbi:9606">Children</span>
###xml 196 201 <span type="species:ncbi:9606">Child</span>
We are grateful to Ron Evans, Meera Ramayya, Masafumi Ito, and Larry Jameson for plasmids. This work was undertaken in part at Great Ormond Street Hospital for Children NHS Trust/UCL Institute of Child Health, which receives a proportion of funding from the Department of Health's NIHR Biomedical Research Centres' funding scheme. J C A holds a Wellcome Trust Senior Research Fellowship in Clinical Science (079666). B K holds a grant of the BMBF Network of Disorders of Sex Development (01GM0628).
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
Toward the effective surveillance of hypospadias
###end article-title 45
###begin article-title 46
International trends in rates of hypospadias and cryptorchidism
###end article-title 46
###begin article-title 47
###xml 3 9 <span type="species:ncbi:9606">humans</span>
In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development
###end article-title 47
###begin article-title 48
The makings of maleness: towards an integrated view of male sexual development
###end article-title 48
###begin article-title 49
Mutation of HOXA13 in hand-foot-genital syndrome
###end article-title 49
###begin article-title 50
FGFR2, FGF8, FGF10 and BMP7 as candidate genes for hypospadias
###end article-title 50
###begin article-title 51
CXorf6 is a causative gene for hypospadias
###end article-title 51
###begin article-title 52
Gonadotrophin resistance
###end article-title 52
###begin article-title 53
Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency
###end article-title 53
###begin article-title 54
###xml 49 54 <span type="species:ncbi:9606">human</span>
The genetics, pathophysiology, and management of human deficiencies of P450c17
###end article-title 54
###begin article-title 55
Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls
###end article-title 55
###begin article-title 56
Etiological studies of severe or familial hypospadias
###end article-title 56
###begin article-title 57
###xml 27 30 <span type="species:ncbi:9606">boy</span>
Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene
###end article-title 57
###begin article-title 58
###xml 99 104 <span type="species:ncbi:9606">human</span>
Coexpression of Wilms' tumor suppressor 1 (WT1) and androgen receptor (AR) in the genital tract of human male embryos and regulation of AR promoter activity by WT1
###end article-title 58
###begin article-title 59
Endocrine disruptors, genital development and hypospadias
###end article-title 59
###begin article-title 60
Steroidogenic factor-1 (SF-1) and its relevance to pediatric endocrinology
###end article-title 60
###begin article-title 61
Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function
###end article-title 61
###begin article-title 62
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency
###end article-title 62
###begin article-title 63
###xml 101 107 <span type="species:ncbi:9606">humans</span>
A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans
###end article-title 63
###begin article-title 64
Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner
###end article-title 64
###begin article-title 65
###xml 56 61 <span type="species:ncbi:9606">human</span>
A novel mutation in the accessory DNA-binding domain of human steroidogenic factor 1 causes XY gonadal dysgenesis without adrenal insufficiency
###end article-title 65
###begin article-title 66
Heterozygous mutation of steroidogenic factor-1 in 46,XY subjects may mimic partial androgen insensitivity syndrome
###end article-title 66
###begin article-title 67
###xml 61 68 <span type="species:ncbi:9606">patient</span>
Gonadal dysgenesis without adrenal insufficiency in a 46, XY patient heterozygous for the nonsense C16X mutation: a case of SF1 haploinsufficiency
###end article-title 67
###begin article-title 68
###xml 63 70 <span type="species:ncbi:9606">patient</span>
Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1
###end article-title 68
###begin article-title 69
###xml 48 53 <span type="species:ncbi:9606">human</span>
A microdeletion in the ligand binding domain of human steroidogenic factor 1 causes XY sex reversal without adrenal insufficiency
###end article-title 69
###begin article-title 70
Mutations in NR5A1 associated with ovarian insufficiency
###end article-title 70
###begin article-title 71
###xml 3 7 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 12 15 <span type="species:ncbi:9606">men</span>
Of mice and men: the tale of steroidogenic factor-1
###end article-title 71
###begin article-title 72
###xml 60 64 <span type="species:ncbi:9606">boys</span>
Mutational analysis of steroidogenic factor 1 (NR5a1) in 24 boys with bilateral anorchia: a French collaborative study
###end article-title 72
###begin article-title 73
Association of severe micropenis with Gly146Ala polymorphism in the gene for steroidogenic factor-1
###end article-title 73
###begin article-title 74
Association of cryptorchidism with Gly146Ala polymorphism in the gene for steroidogenic factor-1
###end article-title 74
###begin article-title 75
Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development
###end article-title 75
###begin article-title 76
Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics
###end article-title 76
###begin article-title 77
Function of steroidogenic factor 1 domains in nuclear localization, transactivation, and interaction with transcription factor TFIIB and c-Jun
###end article-title 77
###begin article-title 78
Determinants of target gene specificity for steroid/thyroid hormone receptors
###end article-title 78
###begin p 79
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">(18)</xref>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">(19)</xref>
###xml 434 440 432 438 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s.e.m.</sc>
###xml 1026 1030 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">(18)</xref>
###xml 1224 1228 1222 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">(33)</xref>
(A) Cartoon of the structure of SF-1 showing the position of the nonsense mutations reported here (p.E11X, p.Q107X) together with that of the previously reported p.Y138X change (18). (B) The p.E11X and p.Q107X mutants show impaired transcriptional activity in an assay using the minimal promoter of Cyp11a in tsa201 cells. The activity of the previously described p.G35E mutant is shown for comparison (19). Data represent the mean+/-s.e.m. of three independent experiments, each performed in triplicate. (-), empty vector; WT, wild-type; RLU, relative lights units. (C) Expression and cellular localization of WT and mutant GFP-SF-1 fusion proteins. WT GFP-SF-1 localizes in the nucleus with relative nucleolar exclusion. A truncated protein corresponding to the p.E11X nonsense mutant reported here is located throughout the cell, whilst low levels of cytoplasmic fusion protein are seen with p.Q107X. In contrast, the previously reported p.Y138X change is strongly localized to the nucleus with signal in the nucleolus too (18). These studies largely support reports that the nuclear localization signal of SF-1 requires codons 89-101 with bipartite basic motifs at either end of this region being particularly important (33).
###end p 79
###begin p 80
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Clinical, biochemical, and genetic characteristics of the three patients with NR5A1 mutations in this series.
###end p 80
###begin p 81
Normal range of: basal testosterone at 7 days 0.12-2.0 ng/ml, 6 months to 7 years <0.1-0.65 ng/ml; LH at 7 days 0.1-1.0 U/l; FSH at 7 days 0.3-4.0 U/l; inhibin B at 0-1 months 68-630 pg/ml, 4-10 years 50-258 pg/ml; anti-Mullerian hormone at 4 years 45-85 ng/ml (conversion factors to SI units are: 3.47 for testosterone (nmol/l), 7.14 for AMH (pmol/l)). Cortisol, DHEAS, and 17-hydroxyprogesterone as markers of basal adrenal function were all normal where studied.
###end p 81
###begin p 82
###xml 62 69 <span type="species:ncbi:9606">patient</span>
Testes/uterus as visualized by ultrasound and/or laparoscopy (patient 2).
###end p 82

